Our studies demonstrated that the LC4-PLG-RGD anti-tumour activity is better than LC4 in vivo, which can infiltrate more CD8+ T cells and CD4+ T cells in tissues, reduce the Treg cell proportion infiltrated by tumour, and weaken the activation ability of T cells in peripheral immune organs. The gene discussed is CD4; the disease is neoplasm.